Financial News: GE Healthcare, Medrad
GE Healthcare saw growth for its PET/CT business with increased market share by over 5 percent to exceed 50 percent of the global market in 2006. This growth occurred in spite of reduced capital equipment purchases for diagnostic imaging modalities that has slowed the PET market growth, GE said.
The company also announced that it will continue to pursue sourcing agreements with its BGO crystal suppliers for its PET and PET/CT systems, the Discovery LS, Discovery ST and Discovery STE.
Medrad reported sales revenues of $478 million in 2006, an increase of 16 percent over the previous year. The medical device company has achieved a 15 percent compounded annual growth in sales for over 10 years. Last year saw the company’s introduction of its Certo MR Wireless Network, which allows the company’s wireless-enabled equipment to travel with the patient from the prep room to the scanner room and then to the recovery area, while maintaining full communication with the remote display on the network. Also, the company’s Stellant and Vistron CT Injection Systems both reached the milestone of 5,000 systems installed worldwide last year.
The company also announced that it will continue to pursue sourcing agreements with its BGO crystal suppliers for its PET and PET/CT systems, the Discovery LS, Discovery ST and Discovery STE.
Medrad reported sales revenues of $478 million in 2006, an increase of 16 percent over the previous year. The medical device company has achieved a 15 percent compounded annual growth in sales for over 10 years. Last year saw the company’s introduction of its Certo MR Wireless Network, which allows the company’s wireless-enabled equipment to travel with the patient from the prep room to the scanner room and then to the recovery area, while maintaining full communication with the remote display on the network. Also, the company’s Stellant and Vistron CT Injection Systems both reached the milestone of 5,000 systems installed worldwide last year.